51 – 100 of 125
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
European Association of Urology Position Statement on Screening for Prostate Cancer.
(
- Contribution to journal › Letter
-
Mark
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
COMPARING TESTOSTERONE AND PSA FOR DIFFERENT BASELINE TESTOSTERONE CONCENTRATIONS DURING INITIATION OF DEGARELIX AND LEUPROLIDE TREATMENT
2009) 24th Annual Congress of the European Association of Urology In European Urology Supplements 8(4). p.130-130(
- Contribution to journal › Published meeting abstract
-
Mark
The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
(
- Contribution to journal › Article
-
Mark
The developing role of hormonal therapy in the treatment of prostate cancer.
(
- Contribution to journal › Article
-
Mark
The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal models.
(
- Contribution to journal › Article
-
Mark
EAU-a work in progress-what comes next?
(
- Contribution to journal › Letter
- 2008
-
Mark
Intermittent DHT administration enhances effect of docetaxel in a xenograft model by modulation of ER beta, AR and NEK2
2008) 23rd Annual Congress of the European Association of Urology, 2008 In European Urology Supplements 7(3). p.278-278(
- Contribution to journal › Published meeting abstract
-
Mark
PSA-based screening for prostate cancer: How does it compare with other cancer screening tests?
(
- Contribution to journal › Scientific review
-
Mark
Reduced risk of prostate cancer in infertile men compared to men with proven fertility: A nested case-control study
2008) 23rd Annual Congress of the European Association of Urology, 2008 In European Urology Supplements 7(3). p.197-197(
- Contribution to journal › Published meeting abstract
-
Mark
The Identification of a Novel Stromal Stem/Progenitor Cell Phenotype in the Human Adult Prostate
2008) 23rd Annual Congress of the European Association of Urology, 2008 In European Urology Supplements 7(3). p.93-93(
- Contribution to journal › Published meeting abstract
-
Mark
Malignant lesions in the ventral prostate of alloxan-induced diabetic rats
(
- Contribution to journal › Article
-
Mark
Hormonal regulation of beta(2)-adrenergic receptor level in prostate cancer
(
- Contribution to journal › Article
-
Mark
Nordic Observational Study Evaluating Safety And Analgesic Use In Patients With Advanced Cancer Under Zoledronic Acid Treatment Interim Analysis
(
- Contribution to journal › Published meeting abstract
-
Mark
Nordic observational study evaluating safety and analgesic consumption in patients with advanced cancer under zoledronic acid (ZOMETA (R)) treatment: NOSAZ-interim analysis
2008) 23rd Annual Congress of the European Association of Urology, 2008 In European Urology Supplements 7(3). p.232-232(
- Contribution to journal › Published meeting abstract
-
Mark
The characterization of epithelial and stromal subsets of candidate stem/progenitor cells in the human adult prostate.
(
- Contribution to journal › Article
-
Mark
Do we need PSA and early detection of prostate cancer?
(
- Contribution to journal › Article
-
Mark
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
(
- Contribution to journal › Article
-
Mark
Prostate cancer and active surveillance.
(
- Contribution to journal › Article
-
Mark
Delta-Like 1 (Dlk-1), a Novel Marker of Prostate Basal and Candidate Epithelial Stem Cells, Is Downregulated by Notch Signalling in Intermediate/Transit Amplifying Cells of the Human Prostate.
(
- Contribution to journal › Article
-
Mark
Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
(
- Contribution to journal › Article
- 2007
-
Mark
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
(
- Contribution to journal › Article
-
Mark
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
(
- Contribution to journal › Article
-
Mark
Active surveillance vs radical prostatectomy.
(
- Contribution to journal › Article
-
Mark
Adjuvant radiotherapy after radical prostatectomy
(
- Contribution to journal › Article
-
Mark
The continuing role of PSA in the detection and management of prostate cancer
(
- Contribution to journal › Article
- 2006
-
Mark
Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer
(
- Contribution to journal › Article
-
Mark
Hormone therapy: Improving therapy decisions and monitoring
(
- Contribution to journal › Article
-
Mark
Interview with Professor Per-Anders Abrahamson: Angiogenesis and renal cell carcinoma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The role of finasteride in the management of BPH and in the prevention of prostate cancer - Introduction
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The Prostate Cancer Prevention Trial and its implications for clinical practice: A European consensus
(
- Contribution to journal › Article
-
Mark
The role of PSA kinetics in the management of prostate cancer
(
- Contribution to journal › Article
-
Mark
Advances in Biomarkers for Prostate Diseases
2006) p.85-85(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2005
-
Mark
Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities
(
- Contribution to journal › Scientific review
-
Mark
The 5alpha-Reductase Type II A49T and V89L High-Activity Allelic Variants are More Common in Men with Prostate Cancer Compared with the General Population.
(
- Contribution to journal › Article
-
Mark
Expression of Serotonin Receptors 2B and 4 in Human Prostate Cancer Tissue and Effects of Their Antagonists on Prostate Cancer Cell Lines.
(
- Contribution to journal › Article
-
Mark
Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.
(
- Contribution to journal › Scientific review
-
Mark
Prognostic value of serum markers for prostate cancer
(
- Contribution to journal › Article
- 2004
-
Mark
Androgen receptor CAG repeat length correlates with semen PSA levels in adolescence.
(
- Contribution to journal › Article
-
Mark
Long-term testosterone stimulation induces hyperplasia in the guinea-pig prostate.
(
- Contribution to journal › Article
-
Mark
Pathophysiology of bone metastases in prostate cancer
(
- Contribution to journal › Article
-
Mark
Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines.
(
- Contribution to journal › Article
-
Mark
Cystatin C is highly expressed in the human male reproductive system.
(
- Contribution to journal › Article
- 2003
-
Mark
No association between mutations in the human androgen receptor GGN repeat and inter-sex conditions
(
- Contribution to journal › Article
-
Mark
Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer
(
- Contribution to journal › Scientific review
-
Mark
Revolutions in the management of hormone-refractory prostate cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Neuroendocrine differentiation in prostatic carcinoma.
(
- Contribution to journal › Article
- 2002
-
Mark
Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines.
(
- Contribution to journal › Article
-
Mark
Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial
(
- Contribution to journal › Article
-
Mark
Neuroendocrine Mediators in Prostate Cancer Progression
2002) p.279-279(
- Chapter in Book/Report/Conference proceeding › Book chapter